Markus Weber

Markus Weber is Professor of Neurology at the University of Basel and serves as chief of the Neuromuscular Diseases Unit/ ALS Clinic at the Kantonsspital St.Gallen in Switzerland. He received his medical degree from the University of Bonn in Germany and  Diploma in Clinical Neurology  from the University of London, Queen Square. Following completion of his residency at various academic hospitals in  Germany and  a neuromuscular fellowship at the University of British Columbia in Vancouver , Canada (1997-2000) he founded the Neuromuscular Diseases Center/ALS Clinic in St.Gallen Switzerland.

His main research interest is in the field of amyotrophic lateral sclerosis and motor neuron disorders and  covers outcome measures, clinical neurophysiology, trial design and cannabinoid research. His work was crucial in developing a motor unit estimation technique called MUNIX as a biomarker for ALS clinical trials. His team has conducted numerous phase I to III clinical trials. In collaboration with the ETH Zürich the first cannabinoid typ 2 radioligand has been developed, which is now available for clinical studies.

Prof. Weber has participated in several EU-funded projects (JPND, eRare) and has received numerous  grants from national funding bodies and various foundations. He has also served on many scientific advisory boards for various biotech companies. Prof. Weber is a member of the ENCALS executive committee and the ENMC research committee and has previously served as co-chair of the European Academy of Neurology scientific panel on ALS and FTD.